Role of mast cells in early epithelial target cell injury in experimental acute graft-versus-host disease.
The skin is a major target organ for graft-versus-host disease (GVHD), the principal complication of allogeneic bone marrow transplantation. The purpose of the present study was to test whether mast cell degranulation might be related to early target cell injury in the development of acute GVHD. We employed two irradiated murine strain combinations, one in which disease was mediated by CD4+ effector T cells (B10.D2-->DBA/2), and the other by CD8+ effector T cells (B10.BR-->CBA). As compared to controls, both models exhibited mast cell degranulation of differing extents and patterns, as well as dyskeratosis in the epidermis before the influx of effector lymphocytes. These results suggested that factors produced and released by degranulated dermal mast cells might contribute to early target cell injury. Accordingly, the possible role of tumor necrosis factor (TNF)-alpha, a cytokine recently discovered in mast cell granules, was investigated by the injection of anti-TNF-alpha antibody during the course of disease mediated by either CD4+ or CD8+ T cells. Although overall survival of recipients undergoing CD4+ T-cell-mediated GVHD was only slightly improved and the extent of mast cell degranulation was not affected by anti-TNF-alpha antibody treatment, the skin exhibited a significant diminution in the number of dyskeratotic cells/linear mm at 3-4 weeks post-transplantation. In contrast, anti-TNF-alpha antibody failed to enhance survival or reduce the number of dyskeratotic cells in the skin during CD8+ T-cell-mediated disease. Finally, to determine whether CD8+ T-cell-mediated GVHD was at all dependent upon mast cell involvement, the C3H.SW-->B6WWv strain combination was utilized, in which recipients were genetically deficient in mast cells. Onset of GVHD was significantly delayed in B6WWv mice and was clearly correlated to the appearance and increase of de novo mast cells at later time points.
Murphy
G F
GF
Department of Dermatology, University of Pennsylvania School of Medicine, Philadelphia.
Sueki
H
H
Teuscher
C
C
Whitaker
D
D
Korngold
R
R
D000818:Animals; D000906:Antibodies; D000954:Antigens, Surface / Q000276:immunology; D001706:Biopsy; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D016827:CD8 Antigens / Q000032:analysis; D015550:Cell Degranulation; D006086:Graft vs Host Disease / Q000209:etiology / Q000276:immunology / Q000503:physiopathology*; D007111:Immunity, Cellular; D008297:Male; D008407:Mast Cells / Q000502:physiology* / Q000648:ultrastructure; D008562:Membrane Glycoproteins / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D008808:Mice, Inbred CBA; D008811:Mice, Inbred DBA; D012867:Skin / Q000166:cytology* / Q000293:injuries*; D013601:T-Lymphocytes / Q000276:immunology; D018800:Thy-1 Antigens; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000502:physiology
D000906:Antibodies; D000954:Antigens, Surface; D016827:CD8 Antigens; D008562:Membrane Glycoproteins; D018800:Thy-1 Antigens; D014409:Tumor Necrosis Factor-alpha